CN106309729A - Traditional Chinese medicine composition for regulating chronic hepatitis immunologic function - Google Patents
Traditional Chinese medicine composition for regulating chronic hepatitis immunologic function Download PDFInfo
- Publication number
- CN106309729A CN106309729A CN201610842840.1A CN201610842840A CN106309729A CN 106309729 A CN106309729 A CN 106309729A CN 201610842840 A CN201610842840 A CN 201610842840A CN 106309729 A CN106309729 A CN 106309729A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- chronic hepatitis
- immunologic function
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 206010008909 Chronic Hepatitis Diseases 0.000 title claims abstract description 15
- 208000006454 hepatitis Diseases 0.000 title claims abstract description 15
- 230000036737 immune function Effects 0.000 title claims abstract description 13
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 17
- 241000190633 Cordyceps Species 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 238000000855 fermentation Methods 0.000 claims description 12
- 230000004151 fermentation Effects 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 5
- 239000012567 medical material Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 235000008504 concentrate Nutrition 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 235000015091 medicinal tea Nutrition 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 244000292693 Poa annua Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 210000002345 respiratory system Anatomy 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 210000005229 liver cell Anatomy 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 10
- 239000002994 raw material Substances 0.000 description 8
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 108010062580 Concanavalin A Proteins 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 230000006058 immune tolerance Effects 0.000 description 5
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- -1 INF-r Proteins 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229960002800 prednisolone acetate Drugs 0.000 description 2
- 239000003390 Chinese drug Substances 0.000 description 1
- 101710142246 External core antigen Proteins 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Abstract
The invention relates to a traditional Chinese medicine composition for regulating the chronic hepatitis immunologic function, and belongs to the technical field of a traditional Chinese medicine composition. The effects of resisting inflammation, protecting liver cells and tonifying deficiency are achieved. The invention particularly relates to a preparation method of the traditional Chinese medicine composition and application thereof to the treatment on patients with chronic hepatitis and abnormal immunologic function with respiratory tract,digestive tract or other tissue organ infection. The traditional Chinese medicine composition is prepared from the following four kinds of common use traditional Chinese medicine including radix angelicae sinensis, fruit of Chinese magnoliavin, barbary wolfberry fruit and fermented cordyceps sinensisbacterial powder, and belongs to the safe and effective traditional Chinese medicine composition. The preparation method is suitable for industrial production, and has good application prospects.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition regulating chronic hepatitis immunologic function, it belongs to technical field of Chinese medicines.
Background technology
The natural history of HBV infection typically experiences 3 periods: immune tolerance, immune clearance phase, not replicated or low duplication
Phase.Patient for immune tolerance is current still without the treatment of specific, concrete.Chinese medicine thinks that HBV is " epidemic disease poison ", is a kind of wet
Hot evil poison, has infectiousness and damage human righteousness.Following Chinese medicine good and evil theoretical, the Mechanism of immunotolerance of CHB can determine that
By vital QI being weakened and pathogen being violent, vital QI cannot conquer pathogen, the evenly matched state at a stalemate formed or mid rally strokes, it is the important rank of epidemic disease poison not easy-clear
Section.Immunologic tolerance is also one of the basic reason that CHB is difficult to cure.
The diagnostic criteria of immune tolerance: serum HBsAg and HBeAg are positive, and HBV DNA carrying capacity height (usually > 106IU/
Ml, is approximately equivalent to 107Copies/ml), but Serum ALT levels is normal, and liver histological Non Apparent Abnormality also can maintain the several years very
To many decades, or mild inflammation necrosis, nothing or the progress of the slowest hepatic fibrosis.
For CHB immunologic tolerance problem, we regulate and control the principle combined with specially good effect side's medicine, develop this immunity in accordance with entirety
Regulation side.
Summary of the invention
For achieving the above object, the technical solution adopted in the present invention is: a kind of Chinese medicine composition, it is to be commonly used by 4 tastes
Medicament, health product or the food that Chinese medicinal material is made.Raw material composition is as follows: Radix Angelicae Sinensis, Fructus Schisandrae Chinensis, Fructus Lycii, and ferment Cordyceps
Mycopowder.
In the immunomodulating Chinese medicine composition of the present invention, the weight portion of each raw material is: Radix Angelicae Sinensis 8-35 part, Fructus Schisandrae Chinensis 5-30 part,
Fructus Lycii 5-30 part, fermentation Cordyceps fungus powder 10-50 part.
Preferably, in the immunomodulating Chinese medicine composition of the present invention, the weight portion of each raw material is: Radix Angelicae Sinensis 10-30 part, the five tastes
Sub-8-25 part, Fructus Lycii 8-25 part, fermentation Cordyceps fungus powder 15-45 part.
It is furthermore preferred that the weight portion of each raw material is in the immunomodulating Chinese medicine composition of the present invention: Radix Angelicae Sinensis 15-25 part, five
Taste 10-20 part, Fructus Lycii 10-20 part, fermentation Cordyceps fungus powder 20-40 part.
Most preferably, in the immunomodulating Chinese medicine composition of the present invention, the weight portion of each raw material is: Radix Angelicae Sinensis 20 parts, Fructus Schisandrae Chinensis
15 parts, Fructus Lycii 15 parts, fermentation Cordyceps fungus powder 30 parts.
In addition, according to the dialectical difference of individual patients, it is also possible to above-mentioned prescription is carried out some and is adjusted flexibly, including
But it is not limited to: increase or alleviate part or all of prescription consumption；Delete constituent part；Increase or replace some soothing livers and strengthening spleens, OK
Gas is invigorated blood circulation, blood stasis dispelling eliminating mass, nourishing the liver and kidney Chinese medicine.
Pharmaceutical composition of the present invention can be prepared as various dosage form, includes but not limited to: decoction, medicinal tea, beverage,
Oral liquid, mixture, granule, capsule, tablet, syrup, pill, drop pill or injection.
Present invention also includes in this Chinese medicine composition preparation regulation chronic hepatitis immune tolerance patient immune function
Application.
The invention have the benefit that this Chinese medicine composition has antiinflammatory, protection hepatocyte, the effect of qi-restoratives, be used for controlling
Treat chronic hepatitis, be applied in the concurrent respiratory tract of immunologic dysfunction, digestive tract or other histoorgans the infected.This Chinese drug-treated group
Compound is made up of following 4 kinds of conventional Chinese medicines: Radix Angelicae Sinensis, Fructus Schisandrae Chinensis, Fructus Lycii, fermentation Cordyceps fungus powder.It is that a kind of safety has
The Chinese medicine composition of effect, its preparation method is suitable for industrialized production, has a good application prospect.
Detailed description of the invention
Below in conjunction with test example and detailed description of the invention, the present invention is described in further detail.But this should not understood
Scope for the above-mentioned theme of the present invention is only limitted to below example, and all technology realized based on present invention belong to this
The scope of invention.
Following embodiment and experimental technique, if no special instructions, be conventional method；Described reagent and medicine, as without special
Different explanation, the most commercially obtains.
Prepared by Part I Chinese medicinal composition preparation of the present invention
Embodiment 1-6 Chinese medicine composition composition powders
Table 1 Chinese medicine composition of the present invention composition powders prescription
| Raw material (g) | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 | Embodiment 6 |
| Radix Angelicae Sinensis | 20 | 25 | 22 | 25 | 16 | 22 |
| Fructus Schisandrae Chinensis | 15 | 13 | 16 | 18 | 18 | 13 |
| Fructus Lycii | 15 | 10 | 15 | 12 | 16 | 20 |
| Fermentation Cordyceps fungus powder | 30 | 35 | 35 | 30 | 32 | 26 |
Embodiment 1 preparation method: take each medical material in compositions, grinds to form powdery according to common process, crosses 100 mesh sieves, and little fire dries
Dry standby, obtain powder.During use, directly take after mixing it with water with after water dissolution.Embodiment 2-6 preparation method is with embodiment 1.
Embodiment 7-12 Chinese medicine composition mixture
Table 2 Chinese medicine composition of the present invention mixture prescription
| Raw material (g) | Embodiment 7 | Embodiment 8 | Embodiment 9 | Embodiment 10 | Embodiment 11 | Embodiment 12 |
| Radix Angelicae Sinensis | 20 | 25 | 22 | 25 | 16 | 22 |
| Fructus Schisandrae Chinensis | 15 | 13 | 16 | 18 | 18 | 13 |
| Fructus Lycii | 15 | 10 | 15 | 12 | 16 | 20 |
| Fermentation Cordyceps fungus powder | 30 | 35 | 35 | 30 | 32 | 26 |
Embodiment 7 preparation method: take each medical material in prescription, according to conventional decocting for Chinese herbal medicine technological operation, filters medicinal residues, and filtrate concentrates
Obtain.Embodiment 8-12 preparation method and using method are with embodiment 7.
Embodiment 13-18 Chinese medicine composition tablet/capsule of the present invention
Table 3 Chinese medicine composition tablet of the present invention/capsule prescription
| Raw material (g) | Embodiment 13 | Embodiment 14 | Embodiment 15 | Embodiment 16 | Embodiment 17 | Embodiment 18 |
| Radix Angelicae Sinensis | 20 | 25 | 22 | 25 | 16 | 22 |
| Fructus Schisandrae Chinensis | 15 | 13 | 16 | 18 | 18 | 13 |
| Fructus Lycii | 15 | 10 | 15 | 12 | 16 | 20 |
| Fermentation Cordyceps fungus powder | 30 | 35 | 35 | 30 | 32 | 26 |
Taking each medical material in prescription, according to conventional decocting for Chinese herbal medicine technological operation, filter, merging filtrate, concentrating under reduced pressure becomes extractum or dry
Cream, adds appropriate amount of auxiliary materials conventional formulation method and makes the receptible tablet of clinical institute or capsule, to obtain final product.
Part II Chinese medicine composition of the present invention pharmacodynamic study
The Chinese medicine composition of the present invention shadow to Concanavalin A (Con A concanavalin A, Con A) induction immunological liver injury in mice
Ring, with serum IL-4, IL-4, INF-r, TNF-a as evaluation index.
Kunming mice 60, is randomly divided into blank group, model control group, positive drug control group, embodiment 1 group, embodiment 7
Group, embodiment 13 groups, often group 10, makees acute immune liver injury model by con A tail vein injection legal system.Make
First 12 days of mould, model control group, blank group give distilled water gavage, positive drug control group give every day prednisolone acetate, remaining
Each group gives embodiment Chinese medicine composition.1 h after last gastric infusion, blank group gives normal saline l0 ml/kg tail vein note
Penetrate, remaining each group according to 20 mg/kg tail vein injection Con A modelings, fasting is freely drunk water.Modeling is plucked eyeball after being administered 8 h and is taken
Blood, centrifugal serum of leaving and taking, the value of mensuration IL-4, IL-6, IFN-r, TNF-a.Each group is administered and dosage is as shown in table 1.
Table 1 is administered and dose form
| Packet | It is administered title | Mice quantity | Administering mode | Dosage |
| Blank group | Distilled water | 10 | Gavage | 10ml/ kg |
| Model control group | Distilled water | 10 | Gavage | 10ml/ kg |
| Prednisolone acetate group | Prednisolone acetate | 10 | Gavage | 7.8mg/kg |
| Embodiment 1 group | Chinese medicine composition suspension | 10 | Gavage | 5g/kg |
| Embodiment 7 groups | Chinese medicine composition suspension | 10 | Gavage | 5g/kg |
| Embodiment 13 groups | Chinese medicine composition suspension | 10 | Gavage | 5g/kg |
With normal group relatively, model group mouse peripheral blood serum IL-4 and IL-6 substantially reduces (* * P < 0. 01), shows that modeling becomes
Merit.Compare with model control group, positive drug control group, each embodiment Chinese medicine composition group mouse peripheral blood serum IL-4 and IL-6
Level have significant change, statistics to have significant difference (* P < 0. 05, * * P < 0. 01).The results are shown in Table 2.
Table 2 respectively organizes mouse peripheral blood serum IL-4 (pg/rnl), the comparison of IL-6 (pg/ml) level
| IL-4(pg/rnl) | IL-6(pg/ml) | |
| Blank group | 68.14±9.73 | 30.26±9.98 |
| Model control group | 45.55 ±6.88** | 12.05 ±6.24** |
| Positive drug control group | 61.79 ±6.18** | 44.25 ±9.29** |
| Embodiment 1 group | 64.45 ±8.66** | 37.10 ± 9.33* |
| Embodiment 7 groups | 66.15 ±8.18** | 36.17 ± 8.27* |
| Embodiment 13 groups | 63.21 ±7.71** | 38.30 ± 9.06* |
Comparing with normal group, model group mouse peripheral blood serum I FN-r, TNF-a level significantly raise (* * P < 0. 01).With
Model control group compares, positive drug control group, each embodiment Chinese medicine composition group mouse peripheral blood serum, significant difference (* * P
< 0. 01, * P < 0. 05).The results are shown in Table 3.
Table 3 respectively organizes mouse peripheral blood serum I FN-r (pg/ml), the comparison of TNF-a (pg/ml) level
| IFN- r (pg/ml) | TNF-a (pg/ml) | |
| Blank group | 2.78 ± 0.89 | 68.42± 9.24 |
| Model control group | 4.46±0.79** | 83.25 ±15.15** |
| Positive drug control group | 3.07 ±0.49* | 77.13 ±12.80* |
| Embodiment 1 group | 2.89 ±1.54** | 65.00 ± 10.95** |
| Embodiment 7 groups | 2.75 ±8.18** | 66.17 ± 12.27** |
| Embodiment 13 groups | 2.81 ±7.71** | 66.90 ± 13.06** |
Claims (7)
1. the Chinese medicine composition regulating chronic hepatitis immunologic function, it is characterised in that described Chinese medicine composition is by following
The crude drug composition of weight portion: Radix Angelicae Sinensis 8-35 part, Fructus Schisandrae Chinensis 5-30 part, Fructus Lycii 5-30 part, fermentation Cordyceps fungus powder 10-50
Part.
A kind of Chinese medicine composition regulating chronic hepatitis immunologic function the most according to claim 1, it is characterised in that described
Chinese medicine composition is made up of the crude drug of following weight portion: Radix Angelicae Sinensis 10-30 part, Fructus Schisandrae Chinensis 8-25 part, Fructus Lycii 8-25 part, fermentation
Cordyceps fungus powder 15-45 part.
A kind of Chinese medicine composition regulating chronic hepatitis immunologic function the most according to claim 1, it is characterised in that described
Chinese medicine composition is made up of the crude drug of following weight portion: Radix Angelicae Sinensis 15-25 part, Fructus Schisandrae Chinensis 10-20 part, Fructus Lycii 10-20 part, send out
Ferment Cordyceps fungus powder 20-40 part.
A kind of Chinese medicine composition regulating chronic hepatitis immunologic function the most according to claim 1, it is characterised in that described
Chinese medicine composition is made up of the crude drug of following weight portion: Radix Angelicae Sinensis 20 parts, Fructus Schisandrae Chinensis 15 parts, Fructus Lycii 15 parts, fermentation worm summer in winter
Grass volvatus powder 30 parts.
5. according to a kind of Chinese medicine composition regulating chronic hepatitis immunologic function described in any one of claim 1-4, its feature
Be: described Chinese medicine composition is used for preparing medicament, health product or food, described medicament health product or food be decoction, medicinal tea,
Beverage, oral liquid, mixture, granule, capsule, tablet, syrup, pill, drop pill or injection.
6. according to a kind of Chinese medicine composition regulating chronic hepatitis immunologic function described in claim 1-4, described Chinese medicine composition
Thing has the purposes improving chronic hepatitis patient immunity.
7. according to the preparation method of a kind of Chinese medicine composition regulating chronic hepatitis immunologic function described in claim 1-4, its
It is characterised by, comprises the following steps:
(1) medical material Radix Angelicae Sinensis, Fructus Schisandrae Chinensis, Fructus Lycii, fermentation Cordyceps fungus powder are weighed in proportion；
(2) add 4-12 times of water according to medical material gross weight, soak 0.5-2 hour, decoct 1-3 time, each 0.5-2.5 hour, merge
Decoction liquor, filters, and concentrates, and adds appropriate amount of auxiliary materials conventional formulation method and makes clinical receptible various dosage forms, to obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610842840.1A CN106309729B (en) | 2016-09-23 | 2016-09-23 | A kind of Chinese medicine composition adjusting chronic hepatitis immune function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610842840.1A CN106309729B (en) | 2016-09-23 | 2016-09-23 | A kind of Chinese medicine composition adjusting chronic hepatitis immune function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106309729A true CN106309729A (en) | 2017-01-11 |
| CN106309729B CN106309729B (en) | 2019-05-14 |
Family
ID=57819711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610842840.1A Active CN106309729B (en) | 2016-09-23 | 2016-09-23 | A kind of Chinese medicine composition adjusting chronic hepatitis immune function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106309729B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109248229A (en) * | 2018-10-16 | 2019-01-22 | 大连博睿森生物医药科技有限公司 | A kind of prevention and treatment immunological liver injury, pharmaceutical composition of drug induced hepatic injury and its preparation method and application |
| CN109248228B (en) * | 2018-10-16 | 2022-02-22 | 锦州医科大学 | Pharmaceutical composition for preventing and treating immunological liver injury and drug-induced liver injury, and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103479683A (en) * | 2012-06-12 | 2014-01-01 | 上海国宝企业发展中心 | North cordyceps sinensis sporophores cultivated in large scale and health care and pharmaceutical application thereof |
-
2016
- 2016-09-23 CN CN201610842840.1A patent/CN106309729B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103479683A (en) * | 2012-06-12 | 2014-01-01 | 上海国宝企业发展中心 | North cordyceps sinensis sporophores cultivated in large scale and health care and pharmaceutical application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 张赤志等主编: "《肝胆病证治精要》", 30 April 1999, 科学技术文献出版社 * |
| 林喆等: "养肝胶囊的药效学研究", 《长春中医学院学报》 * |
| 黄佳宁等: "肝舒胶囊对四氯化碳致小鼠肝损伤的保护作用研究", 《福建医药杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109248229A (en) * | 2018-10-16 | 2019-01-22 | 大连博睿森生物医药科技有限公司 | A kind of prevention and treatment immunological liver injury, pharmaceutical composition of drug induced hepatic injury and its preparation method and application |
| CN109248229B (en) * | 2018-10-16 | 2021-12-24 | 大连润生康泰医学检验实验室有限公司 | Pharmaceutical composition for preventing and treating immunological liver injury and drug-induced liver injury, and preparation method and application thereof |
| CN109248228B (en) * | 2018-10-16 | 2022-02-22 | 锦州医科大学 | Pharmaceutical composition for preventing and treating immunological liver injury and drug-induced liver injury, and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106309729B (en) | 2019-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101596230B (en) | Medicinal composition for treating hepatopathy | |
| CN103990081A (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating infant jaundice | |
| CN102626468B (en) | Traditional Chinese medicine combination for treating hepatitis B and preparing method and application thereof | |
| CN106309729B (en) | A kind of Chinese medicine composition adjusting chronic hepatitis immune function | |
| CN100518809C (en) | Medicinal composition for curing diabetes and nephropathy and its preparing method | |
| CN102657736B (en) | Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition | |
| CN109692309B (en) | Traditional Chinese medicine for treating non-alcoholic fatty liver disease, eliminating dampness and activating blood | |
| CN103705578B (en) | There is blood fat reducing and Chinese medicine preparation suppressing blood glucose rising effect and preparation method thereof | |
| CN104771589A (en) | Traditional Chinese medicine composition for treating fatty liver and application thereof | |
| CN101693068B (en) | Medicament for lowering blood pressure and blood lipid | |
| CN103566349B (en) | A kind of pharmaceutical composition for the treatment of hyperglycemia hyperlipidemia | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN111450143A (en) | Application of ficus microcarpa extract in preparation of medicine for preventing and/or treating liver pathological changes | |
| CN100500189C (en) | Medicament for treating ulcerative colitis and preparation process thereof | |
| CN104147270A (en) | Traditional Chinese medicine for treating acute hepatitis | |
| CN110575521A (en) | Traditional Chinese medicine composition for treating chronic hepatitis B and hepatitis B-related compensatory cirrhosis and application | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN114272349A (en) | Traditional Chinese medicine composition for tonifying spleen and nourishing liver and preparation method and application thereof | |
| CN115120657B (en) | Traditional Chinese medicine composition and pharmaceutical preparation for impervious capacity expansion in burn shock period and preparation method | |
| CN114848764B (en) | Traditional Chinese medicine compound composition for preventing and treating liver injury and preparation method and application thereof | |
| CN110368434B (en) | Compound valerian medicine for treating chronic renal failure and its prepn | |
| CN1319411A (en) | Traditional Chinese medicine compound preparation for treating chronic hepatitis B and preparation process thereof | |
| CN102397430B (en) | Cinobufotalin liver nourishing capsules | |
| CN102631486B (en) | Health care composition | |
| CN101574426A (en) | Chinese patent medicament for treating liver diseases and method for preparing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20171122 Address after: Dalian high tech Industrial Park in Liaoning province 116000 Sata Street No. 13 15 Floor No. 10 Applicant after: Dalian bloomson biological medicine technology Co., Ltd. Applicant after: Jinzhou infectious disease hospital Address before: 121000 27 Fuzhou street, Taihe District, Liaoning, Jinzhou Applicant before: LIAONING RUNSHENG KANGTAI BIOMEDICAL TECHNOLOGY CO., LTD. Applicant before: Jinzhou infectious disease hospital |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190923 Address after: 121000 27 Fuzhou street, Taihe District, Liaoning, Jinzhou Co-patentee after: Jinzhou infectious disease hospital Patentee after: LIAONING RUNSHENG KANGTAI BIOMEDICAL TECHNOLOGY CO., LTD. Address before: Dalian high tech Industrial Park in Liaoning province 116000 Sata Street No. 13 15 Floor No. 10 Co-patentee before: Jinzhou infectious disease hospital Patentee before: Dalian bloomson biological medicine technology Co., Ltd. |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: No.46-6, Huanghai street, Songshan New District, Jinzhou City, Liaoning Province Co-patentee after: JINZHOU INFECTIOUS DISEASE Hospital Patentee after: Liaoning Runsheng Kangtai medical laboratory Co., Ltd Address before: 121000 27 Fuzhou street, Taihe District, Liaoning, Jinzhou Co-patentee before: JINZHOU INFECTIOUS DISEASE Hospital Patentee before: LIAONING RUNSHENG KANGTAI BIOMEDICAL TECHNOLOGY Co.,Ltd. |